(residual neostriatal dopamine levels of more than 10%), lesion-dependent asymmetries in turning behavior were observed in animals that were pre-treated with vehicle-, substance P1-7, or Boc-cholecysto-kinin-4, whereas turning after pre-treatment with substance Ps-was not significantly asymmetrical.
INTRODUCTION
The neurotachykinin substance P (SP) enhances reinforcement and learning and promotes functional recovery after lesions of the nigrostriatal dopamine (DA) system (for review . Furthermore, the evidence shows that these functional effects might be differentially encoded by its C-and N-terminals: The mnemogenic effect of SP is attributed to its N-terminal amino acid sequences, whereas the reinforcing actions of SP are ascribed to the C-terminal (for review see/17-18/). Additionally, neurochemical studies have shown that the reinforcing effects of SP and its C-terminal are related to enhanced DA activity in the ventral striatum/6-8/, whereas the N-terminal fragment SP1-7 had no such effect /6/. Apart from these mnemogenic and reinforcing actions, SP was repeatedly found to exert neurotrophic as well as neuroprotective functions (for example, /19,20, 26,8,39-41/) , and in-vitro investigations showed that this capacity might be related to the N-terminal amino acid sequence. Thus, for example, the N-terminal amino acid sequences of SPI-4, and the dipeptides SP1-2 and SP3-4 were found to enhance neuronal growth/24,25,27/.
Regarding brain lesions, most behaviorally promotive effects of neurokinins have been found in cases of unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal DA system /.2,26,28/. In this hemiparkinsonian model, unilateral damage of nigrostriatal DA neurons leads to ipsi-lateral asymmetries in turning and scanning, from which the animals can recover over time (reviewed in/10,34,35/ No animal had to be discarded because of inaccurate cannula placement. The post-mortem neurochemical analysis showed that in four animals, who had received pre-lesion treatment with SP1-7, neostriatal DA levels on the side of lesion were less than 10% of the intact side; the respective numbers of animals were seven in the SPs_l-group, two in the CCK-4-group, and two in the vehicle-treated group. After the exclusion of these animals, the group sizes were: SP1-7 (n=14), SPs-11 (n=l 1), 
DISCUSSION
This experimem provides the first evidence that systemic pre-treatments of rats with either the C-or the N-terminal fragments of SP can differentially affect the outcome of unilateral, nigrostriatal DA lesions, given that the lesions are partial. Thus, only after excluding animals in which neostriatal DA levels on the side of lesion fell below 10% of the contralateral side, did we observe that the group pre-treated with SPs-11 did not show a significant asymmetry in turning behavior, whereas the other three groups did so. In parallel, neostriatal DA levels on the side of 6-OHDA injection were not significantly decreased in the group pre-treated with SPs-11, in contrast to the groups pre-treated with SP-7, CCK-4, or vehicle, in which the ipsilateral DA levels were lower than those of the contralateral side. Finally, the group treated with showed several indications for changes in striatal DA activity: The contralateral neostriatal DOPAC/DA ratio exceeded those of the other treatment groups, and those of the N-terminal group on the ipsilateral side. Also, in the ventral striatum, the animals that had received the C-terminal fragment of SP displayed higher contralateral DOPAC/DA ratios when compared with the groups treated with the CCK-fragment or vehicle. Thus, this experiment generally supports previous findings that SP can be behaviorally promotive in case of nigrostriatal DA damage, and that this effect may be related to changes in DA mechanisms /2,26,28/. Furthermore, the present study indicates that these effects may be linked to the C-terminal, but not to the N-terminal, of the peptide.
The CCK-fragment In contrast to the C-terminal fragment of SP, pre-lesion treatment with CCK-4 had no effect on tuming behavior, neither in the subsample of animals with partial lesions nor when also including those with more severe lesions. This result extends our previous findings with CCK-8 /28/, wherein pre-lesion treatment did not promote functional recovery. Treatment with CCK-8 affected neostriatal DA activity (namely, increased DOPAC/DA ratios), but had no effect in the ventral striatum/28/, and we assumed that this lack of effect in the ventral striatum was related to that on behavioral recovery. CCK-4 treatment had no DA-activating effect on either structure. Thus, one may conclude either that CCK-4 did not reach the brain in sufficient amounts to be neurochemically effective 
